DOCSLIB.ORG

Pig Antibodies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pig Antibodies Pig Antibodies gene_name sku Entry_Name Protein_Names Organism Length Identity CDX‐2 ARP31476_P050 D0V4H7_PIG Caudal type homeobox 2 (Fragment) Sus scrofa (Pig) 147 100.00% CDX‐2 ARP31476_P050 A7MAE3_PIG Caudal type homeobox transcription factor 2 (Fragment) Sus scrofa (Pig) 75 100.00% Tnnt3 ARP51286_P050 Q75NH3_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 271 85.00% Tnnt3 ARP51286_P050 Q75NH2_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 266 85.00% Tnnt3 ARP51286_P050 Q75NH1_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 260 85.00% Tnnt3 ARP51286_P050 Q75NH0_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 250 85.00% Tnnt3 ARP51286_P050 Q75NG8_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 266 85.00% Tnnt3 ARP51286_P050 Q75NG7_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 260 85.00% Tnnt3 ARP51286_P050 Q75NG6_PIG Troponin T fast skeletal muscle type Sus scrofa (Pig) 250 85.00% Tnnt3 ARP51286_P050 TNNT3_PIG Troponin T, fast skeletal muscle (TnTf) Sus scrofa (Pig) 271 85.00% ORF Names:PANDA_000462 EMBL EFB13877.1OrganismAiluropod High mobility group protein B2 (High mobility group protein a melanoleuca (Giant panda) ARP31939_P050 HMGB2_PIG 2) (HMG‐2) Sus scrofa (Pig) 210 100.00% Agpat5 ARP47429_P050 B8XTR3_PIG 1‐acylglycerol‐3‐phosphate O‐acyltransferase 5 Sus scrofa (Pig) 365 85.00% irf9 ARP31200_P050 Q29390_PIG Transcriptional regulator ISGF3 gamma subunit (Fragment) Sus scrofa (Pig) 57 100.00% irf9 ARP31200_P050 Q0GFA1_PIG Interferon regulatory factor 9 Sus scrofa (Pig) 411 100.00% ARP47492_P050 C8YLT4_PIG LIM homeobox 8 Sus scrofa (Pig) 295 100.00% ORF Names:v1g86891OrganismNem atostella vectensis (Starlet sea anemone) ARP32390_P050 B0FWP7_PIG Sirtuin 5 Sus scrofa (Pig) 310 85.00% ORF Names:v1g86891OrganismNem atostella vectensis (Starlet sea anemone) ARP32390_P050 A7XXV9_PIG Sirtuin 5 Sus scrofa (Pig) 310 85.00% Aebp1 ARP31592_P050 Q1W0S8_PIG AE binding protein (Fragment) Sus scrofa (Pig) 948 100.00% tcf4 ARP33413_P050 C3S7S1_PIG Transcription factor 7‐like 2 (Fragment) Sus scrofa (Pig) 226 100.00% GH‐5 ARP41935_P050 Q53YN7_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 Q4TTE2_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 Q4KVL6_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 Q4KVL5_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 Q4JHT1_PIG Growth hormone (Growth hormone protein) Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 Q28957_PIG Growth hormone Sus scrofa (Pig) 217 100.00% GH‐5 ARP41935_P050 E1U5L2_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BK18_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BJZ2_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BJY8_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BJX8_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BJX2_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BJW5_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BJV7_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BJU4_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BJU3_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BJU2_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BJT8_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BJT5_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BJS9_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 D6BJS8_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 B0ZSN8_PIG Growth hormone Sus scrofa (Pig) 216 100.00% GH‐5 ARP41935_P050 SOMA_PIG Somatotropin (Growth hormone) Sus scrofa (Pig) 216 100.00% Cbp/p300‐interacting transactivator with Glu/Asp‐rich Cited1 ARP32705_P050 Q2VIU2_PIG carboxy‐terminal domain 1 Sus scrofa (Pig) 195 76.00% Adnp ARP39186_P050 A5GHK7_PIG Activity‐dependent neuroprotector Sus scrofa (Pig) 1103 100.00% Heph ARP47078_P050 B3GPD0_PIG Ceruloplasmin (Fragment) Sus scrofa (Pig) 335 92.00% ORF Names:CH211‐145O7.4‐ 001 EMBL CAM12896.1OrganismDanio rerio (Zebrafish) (Brachydanio rerio) ARP31377_P050 FOS_PIG Proto‐oncogene c‐Fos (Cellular oncogene fos) Sus scrofa (Pig) 380 84.00% GATA3 ARP32548_P050 Q6EEH5_PIG GATA binding factor‐3 (Fragment) Sus scrofa (Pig) 94 92.00% GATA3 ARP32548_P050 Q0ZHH4_PIG GATA binding protein 3 Sus scrofa (Pig) 444 92.00% kirrel ARP47408_P050 A0ZQ04_PIG Putative kin of IRRE‐like protein Sus scrofa (Pig) 594 100.00% LEF1 ARP32404_P050 B3GQS6_PIG Lymphoid enhancer‐binding factor‐1 Sus scrofa (Pig) 398 92.00% Ordered Locus Names:Ping_2780OrganismPsyc hromonas ingrahamii (strain 37) ARP41995_P050 Q95N04_PIG Dihydrolipoamide acetyltransferase (EC 2.3.1.12) Sus scrofa (Pig) 647 92.00% Myod1 ARP32134_P050 B5B511_PIG Myogenic factor 5 (Fragment) Sus scrofa (Pig) 161 100.00% Myod1 ARP32134_P050 B5B510_PIG Myogenic factor 5 (Fragment) Sus scrofa (Pig) 161 100.00% Myod1 ARP32134_P050 Q6DTY5_PIG Eukaryotic myogenic factor MYF‐3 (Fragment) Sus scrofa (Pig) 210 78.00% Myod1 ARP32134_P050 D2KPI9_PIG Myogenic differentiation 1 Sus scrofa (Pig) 319 78.00% Myod1 ARP32134_P050 MYOD1_PIG Myoblast determination protein 1 Sus scrofa (Pig) 319 78.00% Myod1 ARP32134_P050 Q866Q1_PIG Myogenic factor 6 (Fragment) Sus scrofa (Pig) 187 78.00% Myod1 ARP32134_P050 Q863T5_PIG Myogenic factor 6 (Fragment) Sus scrofa (Pig) 125 78.00% Myod1 ARP32134_P050 MYF6_PIG Myogenic factor 6 (Myf‐6) Sus scrofa (Pig) 242 78.00% arf‐1 ARP48184_P050 C4MXZ1_PIG ADP‐ribosylation factor 1 Sus scrofa (Pig) 181 100.00% arf‐1 ARP48184_P050 C4MRC5_PIG ADP‐ribosylation factor 2 (ADP‐ribosylation factor 3) Sus scrofa (Pig) 181 100.00% arf‐1 ARP48184_P050 B9V4E8_PIG ADP‐ribosylation factor 2 Sus scrofa (Pig) 181 92.00% POU1F1 ARP31419_P050 Q29012_PIG POU‐domain protein (Fragment) Sus scrofa (Pig) 145 100.00% POU1F1 ARP31419_P050 Q19RW4_PIG POU1F1 (Fragment) Sus scrofa (Pig) 89 100.00% POU1F1 ARP31419_P050 Q19RW3_PIG POU1F1 (Fragment) Sus scrofa (Pig) 89 100.00% POU1F1 ARP31419_P050 D9ZNP5_PIG POU class 1 homeobox 1 Sus scrofa (Pig) 291 100.00% Pituitary‐specific positive transcription factor 1 (PIT‐1) POU1F1 ARP31419_P050 PIT1_PIG (Growth hormone factor 1) (GHF‐1) Sus scrofa (Pig) 291 100.00% POU1F1 ARP31419_P050 O02706_PIG Pit‐1 protein (Fragment) Sus scrofa (Pig) 285 100.00% LOC100036954 ARP43601_P050 OPTN_PIG Optineurin Sus scrofa (Pig) 574 88.00% Inhibitor of kappa light polypeptide gene enhancer in B‐cells LOC100036954 ARP43601_P050 B0LXP7_PIG kinase gamma transcript variant 1 Sus scrofa (Pig) 411 84.00% Inhibitor of kappa light polypeptide gene enhancer in B‐cells LOC100036954 ARP43601_P050 A9QT41_PIG kinase gamma Sus scrofa (Pig) 419 84.00% ARP31477_P050 B5U335_PIG Solute carrier family 30 member 9 Sus scrofa (Pig) 566 100.00% Hepatocyte nuclear factor 1‐beta (HNF‐1‐beta) (HNF‐1B) (FPC‐ Hnf1b ARP32320_P050 HNF1B_PIG binding protein) (FPCB) (Transcription factor 2) (TCF‐2) Sus scrofa (Pig) 559 100.00% TFAM ARP31400_P050 Q9GL64_PIG Transcription factor A (Fragment) Sus scrofa (Pig) 149 91.00% TFAM ARP31400_P050 TFAM_PIG Transcription factor A, mitochondrial (mtTFA) Sus scrofa (Pig) 246 91.00% ORF Names:ACLA_068740 Aspartate aminotransferase, mitochondrial (mAspAT) (EC EMBL 2.6.1.1) (Fatty acid‐binding protein) (FABP‐1) (Glutamate EAW13846.1OrganismAspergill oxaloacetate transaminase 2) (Plasma membrane‐associated us clavatus ARP43517_T100 AATM_PIG fatty acid‐binding protein) (FABPpm) (Transaminase A) Sus scrofa (Pig) 430 100.00% CLDN1 ARP33623_P050 C3VMK8_PIG Claudin 1 Sus scrofa (Pig) 211 92.00% CLDN1 ARP33623_P050 B5U6Z3_PIG Claudin 1 (EC 3.4.22.65) (Fragment) Sus scrofa (Pig) 184 92.00% TBX21 ARP32612_P050 Q6T5D5_PIG T‐box 21 (Fragment) Sus scrofa (Pig) 66 100.00% ARP48627_P050 C5HA00_PIG DNA methyltransferase 2 Sus scrofa (Pig) 408 100.00% NF‐kappa‐B inhibitor alpha (ECI‐6) (I‐kappa‐B‐alpha) (IkB‐ P100940_P050 IKBA_PIG alpha) (IkappaBalpha) Sus scrofa (Pig) 314 76.00% hoxd4b ARP39383_P050 E1U314_PIG Homeobox A5 Sus scrofa (Pig) 270 100.00% SIX1 ARP32383_P050 E5DCJ4_PIG Six homeobox 1 Sus scrofa (Pig) 284 78.00% Lin7c ARP42907_P050 E5DCJ4_PIG Six homeobox 1 Sus scrofa (Pig) 284 78.00% Park7 ARP51267_P050 Q0R678_PIG DJ‐1 protein Sus scrofa (Pig) 189 100.00% ARP41479_P050 Q2HYU1_PIG Mitochondrial creatine kinase 2 Sus scrofa (Pig) 419 100.00% ARP51293_P050 Q5DKX3_PIG P2Y1 receptor (Fragment) Sus scrofa (Pig) 268 100.00% Ordered Locus Names:Maqu_2399OrganismM arinobacter aquaeolei (strain ATCC 700491 / DSM 11845 / VT8) (Marinobacter hydrocarbonoclasticus (strain Long‐chain specific acyl‐CoA dehydrogenase, mitochondrial DSM 11845)) ARP33856_P050 ACADL_PIG (LCAD) (EC 1.3.99.13) Sus scrofa (Pig) 430 100.00% ATG4B ARP57862_P050 D7RA22_PIG Autophagy related 4‐like protein B Sus scrofa (Pig) 393 84.00% CXADR ARP33080_P050 Q9TU79_PIG Coxsackie‐adenovirus‐receptor homolog (Fragment) Sus scrofa (Pig) 319 92.00% CXADR ARP32757_P050 Q9TU79_PIG Coxsackie‐adenovirus‐receptor homolog (Fragment) Sus scrofa (Pig) 319 92.00% Acyl coenzyme A synthetase long‐chain 1 (EC 6.2.1.3) ARP32784_P050 Q6B339_PIG (Fragment) Sus scrofa (Pig) 683 76.00% CCDC117 AVARP09013_P050 Q6EEH9_PIG Regulator of G‐protein signalling 10 (Fragment) Sus scrofa (Pig) 46 90.00% TRIM27.2 ARP57848_P050 B6ICU9_PIG Tripartite motif‐containing protein 10 Sus scrofa (Pig) 482 84.00% Tripartite motif‐containing protein 10 (B30‐RING finger TRIM27.2 ARP57848_P050 TRI10_PIG protein) (RING finger protein 9)
Load more

Recommended publications
  • Detection of Interacting Transcription Factors in Human Tissues Using
    Myšičková and Vingron BMC Genomics 2012, 13(Suppl 1):S2 http://www.biomedcentral.com/1471-2164/13/S1/S2 PROCEEDINGS Open Access Detection of interacting transcription factors in human tissues using predicted DNA binding affinity Alena Myšičková*, Martin Vingron From The Tenth Asia Pacific Bioinformatics Conference (APBC 2012) Melbourne, Australia. 17-19 January 2012 Abstract Background: Tissue-specific gene expression is generally regulated by combinatorial interactions among transcription factors (TFs) which bind to the DNA. Despite this known fact, previous discoveries of the mechanism that controls gene expression usually consider only a single TF. Results: We provide a prediction of interacting TFs in 22 human tissues based on their DNA-binding affinity in promoter regions. We analyze all possible pairs of 130 vertebrate TFs from the JASPAR database. First, all human promoter regions are scanned for single TF-DNA binding affinities with TRAP and for each TF a ranked list of all promoters ordered by the binding affinity is created. We then study the similarity of the ranked lists and detect candidates for TF-TF interaction by applying a partial independence test for multiway contingency tables. Our candidates are validated by both known protein-protein interactions (PPIs) and known gene regulation mechanisms in the selected tissue. We find that the known PPIs are significantly enriched in the groups of our predicted TF-TF interactions (2 and 7 times more common than expected by chance). In addition, the predicted interacting TFs for studied tissues (liver, muscle, hematopoietic stem cell) are supported in literature to be active regulators or to be expressed in the corresponding tissue.
    [Show full text]
  • Table S1. List of Proteins in the BAHD1 Interactome
    Table S1. List of proteins in the BAHD1 interactome BAHD1 nuclear partners found in this work yeast two-hybrid screen Name Description Function Reference (a) Chromatin adapters HP1α (CBX5) chromobox homolog 5 (HP1 alpha) Binds histone H3 methylated on lysine 9 and chromatin-associated proteins (20-23) HP1β (CBX1) chromobox homolog 1 (HP1 beta) Binds histone H3 methylated on lysine 9 and chromatin-associated proteins HP1γ (CBX3) chromobox homolog 3 (HP1 gamma) Binds histone H3 methylated on lysine 9 and chromatin-associated proteins MBD1 methyl-CpG binding domain protein 1 Binds methylated CpG dinucleotide and chromatin-associated proteins (22, 24-26) Chromatin modification enzymes CHD1 chromodomain helicase DNA binding protein 1 ATP-dependent chromatin remodeling activity (27-28) HDAC5 histone deacetylase 5 Histone deacetylase activity (23,29,30) SETDB1 (ESET;KMT1E) SET domain, bifurcated 1 Histone-lysine N-methyltransferase activity (31-34) Transcription factors GTF3C2 general transcription factor IIIC, polypeptide 2, beta 110kDa Required for RNA polymerase III-mediated transcription HEYL (Hey3) hairy/enhancer-of-split related with YRPW motif-like DNA-binding transcription factor with basic helix-loop-helix domain (35) KLF10 (TIEG1) Kruppel-like factor 10 DNA-binding transcription factor with C2H2 zinc finger domain (36) NR2F1 (COUP-TFI) nuclear receptor subfamily 2, group F, member 1 DNA-binding transcription factor with C4 type zinc finger domain (ligand-regulated) (36) PEG3 paternally expressed 3 DNA-binding transcription factor with
    [Show full text]
  • Supplementary Materials: Evaluation of Cytotoxicity and Α-Glucosidase Inhibitory Activity of Amide and Polyamino-Derivatives of Lupane Triterpenoids
    Supplementary Materials: Evaluation of cytotoxicity and α-glucosidase inhibitory activity of amide and polyamino-derivatives of lupane triterpenoids Oxana B. Kazakova1*, Gul'nara V. Giniyatullina1, Akhat G. Mustafin1, Denis A. Babkov2, Elena V. Sokolova2, Alexander A. Spasov2* 1Ufa Institute of Chemistry of the Ufa Federal Research Centre of the Russian Academy of Sciences, 71, pr. Oktyabrya, 450054 Ufa, Russian Federation 2Scientific Center for Innovative Drugs, Volgograd State Medical University, Novorossiyskaya st. 39, Volgograd 400087, Russian Federation Correspondence Prof. Dr. Oxana B. Kazakova Ufa Institute of Chemistry of the Ufa Federal Research Centre of the Russian Academy of Sciences 71 Prospeсt Oktyabrya Ufa, 450054 Russian Federation E-mail: [email protected] Prof. Dr. Alexander A. Spasov Scientific Center for Innovative Drugs of the Volgograd State Medical University 39 Novorossiyskaya st. Volgograd, 400087 Russian Federation E-mail: [email protected] Figure S1. 1H and 13C of compound 2. H NH N H O H O H 2 2 Figure S2. 1H and 13C of compound 4. NH2 O H O H CH3 O O H H3C O H 4 3 Figure S3. Anticancer screening data of compound 2 at single dose assay 4 Figure S4. Anticancer screening data of compound 7 at single dose assay 5 Figure S5. Anticancer screening data of compound 8 at single dose assay 6 Figure S6. Anticancer screening data of compound 9 at single dose assay 7 Figure S7. Anticancer screening data of compound 12 at single dose assay 8 Figure S8. Anticancer screening data of compound 13 at single dose assay 9 Figure S9. Anticancer screening data of compound 14 at single dose assay 10 Figure S10.
    [Show full text]
  • Active Rac1 Detection Kit 2012 09/20
    Active Rac1 Detection Kit 1 Kit Orders n 877-616-CELL (2355) (30 immunoprecipitations) [email protected] Support n 877-678-TECH (8324) [email protected] Web n www.cellsignal.com rev. 09/24/20 #8815 For Research Use Only. Not For Use In Diagnostic Procedures. Species Cross-Reactivity: H, M Components Ship As: 11894S Item # Kit Quantity Storage Temp Description: The Active Rac1 Detection Kit provides all GTPgS 11521 1 X 50 µl –80°C reagents necessary for measuring activation of Rac1 GTPase in the cell. GST-PAK1-PBD fusion protein is used to bind GDP 11522 1 X 50 µl –80°C the activated form of GTP-bound Rac1, which can then be Components Ship As: 11894S Item # Kit Quantity Storage Temp immunoprecipitated with glutathione resin. Rac1 activation levels are then determined by western blot using a Rac1 GST-Human PAK1-PBD 8659 1 X 600 µg –20°C Mouse mAb. Rac1 Mouse mAb 8631 1 X 50 µl –20°C Specificity/Sensitivity: Active Rac1 Detection Kit detects Components Ship As: 11860S Item # Kit Quantity Storage Temp endogenous levels of GTP-bound (active) Rac1 as shown in Lysis/Binding/Wash Buffer 11524 1 X 100 mL 4°C Figure 1. This kit detects proteins from the indicated species, as determined through in-house testing, but may also detect Glutathione Resin 11523 1 X 3 ml 4°C homologous proteins from other species. SDS Sample Buffer 11525 1 X 1.5 ml 4°C Background: The Ras superfamily of small GTP-binding Spin Cup and Collection Tubes 11526 1 X 30 vial RT proteins (G proteins) comprise a large class of proteins (over 150 members) that can be classified into at least five families based on their sequence and functional similarities: 1 2 3 4 Figure 1.
    [Show full text]
  • FHL3 Contributes to EMT and Chemotherapy Resistance Through Inhibiting Ubiquitination of Slug and Activating Tgfβ/Smad-Independent Pathways in Gastric Cancer
    FHL3 Contributes to EMT and Chemotherapy Resistance Through Inhibiting Ubiquitination of Slug and Activating TGFβ/Smad-Independent Pathways in Gastric Cancer Guodong Cao First Aliated Hospital of Anhui Medical University Pengping Li Hangzhou Xiaoshan No 1 People's Hospital Qiang Sun Xuzhou Medical University Sihan Chen First Aliated Hospital of Anhui Medical University Xin Xu First Aliated Hospital of Anhui Medical University Xiaobo He First Aliated Hospital of Anhui Medical University Zhenyu Wang Hangzhou Xiaoshan No 1 People's Hospital Peng Chen First Aliated Hospital of Anhui Medical University Maoming Xiong ( [email protected] ) First Aliated Hospital of Anhui Medical University Bo Chen First Aliated Hospital of Anhui Medical University Research Keywords: EMT, Chemotherapy resistance, FHL3, Ubiquitination, Gastric cancer Posted Date: October 9th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-87249/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. ReLoaadd iFngu l[Ml LaitchJeanxs]/ejax/output/CommonHTML/jax.js Page 1/28 Loading [MathJax]/jax/output/CommonHTML/jax.js Page 2/28 Abstract Background: Gastric cancer presents high risk of metastasis and chemotherapy resistance. Hence, the mechanistic understanding of the tumor metastasis and chemotherapy resistance is quietly important. Methods: TCGA database and clinical samples are used for exploring the role of FHL3 in disease progression and prognosis. The roles of FHL3 in metastasis and chemotherapy resistance are explored in vitro and in vivo by siRNA or shRNA treatment. Finally, we explore the FHL3-mediated EMT and chemotherapy resistance. Results: mRNA and protein level of FHL3 is signicantly up-regulated in gastric cancer tissues when compares with it in adjacent tissue.
    [Show full text]
  • In Vivo Studies Using the Classical Mouse Diversity Panel
    The Mouse Diversity Panel Predicts Clinical Drug Toxicity Risk Where Classical Models Fail Alison Harrill, Ph.D The Hamner-UNC Institute for Drug Safety Sciences 0 The Importance of Predicting Clinical Adverse Drug Reactions (ADR) Figure: Cath O’Driscoll Nature Publishing 2004 Risk ID PGx Testing 1 People Respond Differently to Drugs Pharmacogenetic Markers Identified by Genome-Wide Association Drug Adverse Drug Risk Allele Reaction (ADR) Abacavir Hypersensitivity HLA-B*5701 Flucloxacillin Hepatotoxicity Allopurinol Cutaneous ADR HLA-B*5801 Carbamazepine Stevens-Johnson HLA-B*1502 Syndrome Augmentin Hepatotoxicity DRB1*1501 Ximelagatran Hepatotoxicity DRB1*0701 Ticlopidine Hepatotoxicity HLA-A*3303 Average preclinical populations and human hepatocytes lack the diversity to detect incidence of adverse events that occur only in 1/10,000 people. Current Rodent Models of Risk Assessment The Challenge “At a time of extraordinary scientific progress, methods have hardly changed in several decades ([FDA] 2004)… Toxicologists face a major challenge in the twenty-first century. They need to embrace the new “omics” techniques and ensure that they are using the most appropriate animals if their discipline is to become a more effective tool in drug development.” -Dr. Michael Festing Quantitative geneticist Toxicol Pathol. 2010;38(5):681-90 Rodent Models as a Strategy for Hazard Characterization and Pharmacogenetics Genetically defined rodent models may provide ability to: 1. Improve preclinical prediction of drugs that carry a human safety risk 2.
    [Show full text]
  • Detailed Review Paper on Retinoid Pathway Signalling
    1 1 Detailed Review Paper on Retinoid Pathway Signalling 2 December 2020 3 2 4 Foreword 5 1. Project 4.97 to develop a Detailed Review Paper (DRP) on the Retinoid System 6 was added to the Test Guidelines Programme work plan in 2015. The project was 7 originally proposed by Sweden and the European Commission later joined the project as 8 a co-lead. In 2019, the OECD Secretariat was added to coordinate input from expert 9 consultants. The initial objectives of the project were to: 10 draft a review of the biology of retinoid signalling pathway, 11 describe retinoid-mediated effects on various organ systems, 12 identify relevant retinoid in vitro and ex vivo assays that measure mechanistic 13 effects of chemicals for development, and 14 Identify in vivo endpoints that could be added to existing test guidelines to 15 identify chemical effects on retinoid pathway signalling. 16 2. This DRP is intended to expand the recommendations for the retinoid pathway 17 included in the OECD Detailed Review Paper on the State of the Science on Novel In 18 vitro and In vivo Screening and Testing Methods and Endpoints for Evaluating 19 Endocrine Disruptors (DRP No 178). The retinoid signalling pathway was one of seven 20 endocrine pathways considered to be susceptible to environmental endocrine disruption 21 and for which relevant endpoints could be measured in new or existing OECD Test 22 Guidelines for evaluating endocrine disruption. Due to the complexity of retinoid 23 signalling across multiple organ systems, this effort was foreseen as a multi-step process.
    [Show full text]
  • Bioinformatic Analysis of Structure and Function of LIM Domains of Human Zyxin Family Proteins
    International Journal of Molecular Sciences Article Bioinformatic Analysis of Structure and Function of LIM Domains of Human Zyxin Family Proteins M. Quadir Siddiqui 1,† , Maulik D. Badmalia 1,† and Trushar R. Patel 1,2,3,* 1 Alberta RNA Research and Training Institute, Department of Chemistry and Biochemistry, University of Lethbridge, 4401 University Drive, Lethbridge, AB T1K 3M4, Canada; [email protected] (M.Q.S.); [email protected] (M.D.B.) 2 Department of Microbiology, Immunology and Infectious Disease, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive, Calgary, AB T2N 4N1, Canada 3 Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada * Correspondence: [email protected] † These authors contributed equally to the work. Abstract: Members of the human Zyxin family are LIM domain-containing proteins that perform critical cellular functions and are indispensable for cellular integrity. Despite their importance, not much is known about their structure, functions, interactions and dynamics. To provide insights into these, we used a set of in-silico tools and databases and analyzed their amino acid sequence, phylogeny, post-translational modifications, structure-dynamics, molecular interactions, and func- tions. Our analysis revealed that zyxin members are ohnologs. Presence of a conserved nuclear export signal composed of LxxLxL/LxxxLxL consensus sequence, as well as a possible nuclear localization signal, suggesting that Zyxin family members may have nuclear and cytoplasmic roles. The molecular modeling and structural analysis indicated that Zyxin family LIM domains share Citation: Siddiqui, M.Q.; Badmalia, similarities with transcriptional regulators and have positively charged electrostatic patches, which M.D.; Patel, T.R.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supplemental Materials ZNF281 Enhances Cardiac Reprogramming
    Supplemental Materials ZNF281 enhances cardiac reprogramming by modulating cardiac and inflammatory gene expression Huanyu Zhou, Maria Gabriela Morales, Hisayuki Hashimoto, Matthew E. Dickson, Kunhua Song, Wenduo Ye, Min S. Kim, Hanspeter Niederstrasser, Zhaoning Wang, Beibei Chen, Bruce A. Posner, Rhonda Bassel-Duby and Eric N. Olson Supplemental Table 1; related to Figure 1. Supplemental Table 2; related to Figure 1. Supplemental Table 3; related to the “quantitative mRNA measurement” in Materials and Methods section. Supplemental Table 4; related to the “ChIP-seq, gene ontology and pathway analysis” and “RNA-seq” and gene ontology analysis” in Materials and Methods section. Supplemental Figure S1; related to Figure 1. Supplemental Figure S2; related to Figure 2. Supplemental Figure S3; related to Figure 3. Supplemental Figure S4; related to Figure 4. Supplemental Figure S5; related to Figure 6. Supplemental Table S1. Genes included in human retroviral ORF cDNA library. Gene Gene Gene Gene Gene Gene Gene Gene Symbol Symbol Symbol Symbol Symbol Symbol Symbol Symbol AATF BMP8A CEBPE CTNNB1 ESR2 GDF3 HOXA5 IL17D ADIPOQ BRPF1 CEBPG CUX1 ESRRA GDF6 HOXA6 IL17F ADNP BRPF3 CERS1 CX3CL1 ETS1 GIN1 HOXA7 IL18 AEBP1 BUD31 CERS2 CXCL10 ETS2 GLIS3 HOXB1 IL19 AFF4 C17ORF77 CERS4 CXCL11 ETV3 GMEB1 HOXB13 IL1A AHR C1QTNF4 CFL2 CXCL12 ETV7 GPBP1 HOXB5 IL1B AIMP1 C21ORF66 CHIA CXCL13 FAM3B GPER HOXB6 IL1F3 ALS2CR8 CBFA2T2 CIR1 CXCL14 FAM3D GPI HOXB7 IL1F5 ALX1 CBFA2T3 CITED1 CXCL16 FASLG GREM1 HOXB9 IL1F6 ARGFX CBFB CITED2 CXCL3 FBLN1 GREM2 HOXC4 IL1F7
    [Show full text]
  • Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
    www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1.
    [Show full text]
  • HMGB1 in Health and Disease R
    Donald and Barbara Zucker School of Medicine Journal Articles Academic Works 2014 HMGB1 in health and disease R. Kang R. C. Chen Q. H. Zhang W. Hou S. Wu See next page for additional authors Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles Part of the Emergency Medicine Commons Recommended Citation Kang R, Chen R, Zhang Q, Hou W, Wu S, Fan X, Yan Z, Sun X, Wang H, Tang D, . HMGB1 in health and disease. 2014 Jan 01; 40():Article 533 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/533. Free full text article. This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. Authors R. Kang, R. C. Chen, Q. H. Zhang, W. Hou, S. Wu, X. G. Fan, Z. W. Yan, X. F. Sun, H. C. Wang, D. L. Tang, and +8 additional authors This article is available at Donald and Barbara Zucker School of Medicine Academic Works: https://academicworks.medicine.hofstra.edu/articles/533 NIH Public Access Author Manuscript Mol Aspects Med. Author manuscript; available in PMC 2015 December 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Mol Aspects Med. 2014 December ; 0: 1–116. doi:10.1016/j.mam.2014.05.001. HMGB1 in Health and Disease Rui Kang1,*, Ruochan Chen1, Qiuhong Zhang1, Wen Hou1, Sha Wu1, Lizhi Cao2, Jin Huang3, Yan Yu2, Xue-gong Fan4, Zhengwen Yan1,5, Xiaofang Sun6, Haichao Wang7, Qingde Wang1, Allan Tsung1, Timothy R.
    [Show full text]